Ligand Pharmaceuticals Incorporated (LGND)
| Market Cap | 5.59B +79.3% |
| Revenue (ttm) | 290.54M +54.9% |
| Net Income | 197.22M |
| EPS | 9.19 |
| Shares Out | 19.94M |
| PE Ratio | 30.51 |
| Forward PE | 40.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,691 |
| Open | 283.70 |
| Previous Close | 284.52 |
| Day's Range | 277.36 - 284.00 |
| 52-Week Range | 158.40 - 326.63 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 342.82 (+22.22%) |
| Earnings Date | Aug 6, 2026 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price target is $342.82, which is an increase of 22.22% from the latest price.
News
Ligand Pharmaceuticals Transcript: 17th Annual Midwest IDEAS Conference
The company has rapidly scaled its royalty aggregation strategy, highlighted by the XOMA acquisition, which doubled its portfolio and is immediately accretive. Strong financials, a robust pipeline, and disciplined investment processes position it for significant near- and long-term growth.
Ligand to Participate in September Investor Conferences
JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor confe...
Ligand Pharmaceuticals Slides: Corporate presentation
Ligand Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Ligand Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw revenue and EPS surge, driven by strong royalty growth and the transformative XOMA acquisition, which doubled the late-stage pipeline and added over 120 assets. The company raised $700 million in zero coupon convertible notes, reaffirmed robust guidance, and expects significant near-term catalysts across a diversified portfolio.
Ligand Pharmaceuticals Earnings release: Q2 2026
Ligand Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q2 2026
Ligand Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Ligand Pharmaceuticals Quarterly report: Q2 2026
Ligand Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
JUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 202...
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating...
XOMA Royalty Announces Closing of Its Acquisition by Ligand
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisitio...
Ligand Announces Closing of Convertible Senior Notes Offering
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset...
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offse...
Ligand Announces 2026 Investor Day in New York City
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 1...
Ligand to Participate in June Investor Conferences
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Ligand Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% royalty revenue and 23% adjusted EPS growth year-over-year, driven by portfolio expansion and the strategic shift to royalty aggregation. The XOMA Royalty acquisition is expected to be immediately accretive, further diversifying assets and accelerating long-term growth.
Ligand Pharmaceuticals Earnings release: Q1 2026
Ligand Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Ligand Pharmaceuticals Slides: Q1 2026
Ligand Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Ligand Pharmaceuticals Quarterly report: Q1 2026
Ligand Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Ligand Reports First Quarter 2026 Financial Results
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution ...
Ligand to Participate in May Investor Conferences
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor c...
Ligand Pharmaceuticals Proxy statement: Proxy filing
Ligand Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo...
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.